PRISMATIC : Prescription Risk Inspection System for Multi-Agent Treatment Interaction in Clinical Decision-Making
Multimorbid prescribing is a high-stakes coordination problem: patients with multiple chronic conditions receive fragmented, single-disease treatment plans that frequently trigger adverse drug events. PRISMATIC addresses this by treating prescription generation as a multi-agent synthesis task rather than monolithic text generation. The system deploys six specialized agents—ranging from information extraction to safety and rationality critics—on a shared blackboard, coordinated by an inner iterative-refinement loop (DFPC) and an outer long-term weight-adaptation loop (DSWA). The work matters because it reframes clinical AI safety as an explicit multi-objective coordination problem, moving beyond end-to-end LLM output toward modular, auditable reasoning.
PRISMATIC presents an architecturally thoughtful response to multimorbid prescribing, but its central empirical and conceptual claims need stronger support. The absolute exact-match rate of $13.58\%$ on the complete dataset—while double the strongest baseline—still represents a system that diverges from clinical practice on the majority of cases, a point the authors acknowledge when noting that the score "underscores the profound difficulty of fully replicating the nuanced decision-making of human clinicians" (Section 6.2). More fundamentally, the experimental gold standard comprises historical MIMIC-IV prescription orders, which may embed the very suboptimal polypharmacy and coordination failures the paper seeks to remedy. Without prospective clinician validation, the clinical significance of the safety and coverage metrics remains uncertain.
The ablation study is the strongest evidence in the paper. Removing the Safety Check agent drops the Zero-Interaction Ratio from $98.20\%$ to $78.98\%$, confirming that "an explicit, dedicated safety agent is non-negotiable for generating clinically safe prescriptions" (Section 5.3), while removing the Pharmacological Rationality agent cuts Overlap Rate from $56.81\%$ to $44.13\%$. The problem formulation itself is clean and clinically grounded: safety formalized as $\forall i \neq j: \textbf{DDI}_P(d_i,d_j)=0$ and dosage bounds, rationality as coverage minus duplication, and interpretability as auditable evidence (Section 3.1). The targeted, localized correction mechanism in DFPC—"trace a specific violation back to its source domain and re-engage only the relevant agents" (Section 4.2)—is computationally efficient and mimics real-world peer review.
The most serious flaw is the mischaracterization of prior work. The authors introduce the paper by claiming current approaches frame prescribing as "a monolithic, end-to-end generation problem, ingesting all patient data to produce an output in an opaque, 'black box' fashion ([Kim et al., 2024]; [Chen et al., 2025a]; [Pan et al., 2025])" (Introduction), yet Kim et al., 2024 is the explicitly multi-agent MDAgents framework, and Chen et al., 2025a is titled "Enhancing diagnostic capability with multi-agents conversational large language models." This contradiction undermines the novelty claim and suggests the authors did not carefully distinguish their contribution from structurally similar prior systems, even while their own related-work section notes that Kim et al. presents "adaptive frameworks mimicking real-world clinical decision-making" (Section 2). Beyond framing, the task itself is weakened by using historical EHR prescriptions as gold standard without expert curation, risking circular evaluation. The authors partially admit these limitations, noting the system "sometimes omits secondary medications for symptomatic relief or preemptive care" and "cannot yet infer the subtle, unwritten context" of notes (Section 6.2), but these concessions emphasize how far the system is from clinical deployment.
The benchmark suite is extensive, testing four base LLMs under six prompting strategies plus specialized medical models, and fair in one respect: PRISMATIC agents use "the same suite of base models as the baselines" (Section 5.1). However, the comparison is operationally uneven because PRISMATIC's agents appear to query formal safety constraints (Table 1 footnote: $\forall i \neq j: \textbf{DDI}_P(d_i,d_j)=0$; dosage $u_i \in [u^{min}_i, u^{max}_i]$) that monolithic baselines lack unless given equivalent tool access, conflating architecture with privileged knowledge. Moreover, the omission of multi-agent baselines like MDAgents from the empirical comparison prevents isolation of DFPC and DSWA value. Statistical robustness is also unclear because Table 2 reports point estimates without standard deviations or confidence intervals across random seeds.
Independent replication would be severely hampered. The paper provides no code, prompts, or curated dataset release, and omits essential algorithmic details: the DDI/DPI knowledge base and dosage lookup tables are unnamed, DSWA hyperparameters ($\gamma$, $\eta$, $\beta$) are listed in Algorithm 1 but never assigned numeric values or sensitivity analysis, and the K-means stratification specifying case complexity is not accompanied by feature lists or random seeds ("stratified the dataset ... with K-means," Section 5.1). The blackboard mediation rules and termination criteria for the DFPC loop are described only conceptually. Without these artifacts, the reported $99.20\%$ ZIR and exact-match gains cannot be independently verified.
Medical prescribing errors for multimorbid patients, who require complex drug regimens, are a major patient safety concern. These errors often stem from fragmented decision-making across medical specialties, a critical coordination failure that leads to adverse drug events and rehospitalizations. To address this coordination challenge, we introduce PRISMATIC, a multi-agent architecture where specialized agents, each representing a workflow role, collaboratively generate and refine treatment plans. Operating on a blackboard architecture, the system first structures patient information from clinical notes, then iteratively develops safe, rational, and interpretable drug regimens. The agents' collaboration is governed by two novel adaptive coordination mechanisms: (1) Dynamic Self-Updating Weight Adjustment (DSWA), a long-term mechanism that adjusts the influence weights of agents based on historical case outcomes, enabling the system to adapt and trust more reliable specialists over time. (2) Discrepancy Feedback Precise Calibration (DFPC), a short-term mechanism where agents provide iterative feedback to resolve disagreements and eliminate prescription conflicts for the current patient. Experiments on patient records from the MIMIC-IV database show that PRISMATIC significantly reduces drug conflicts, improves prescription coverage, and enhances treatment consistency compared to strong LLM baselines. Our work demonstrates that structuring clinical co-treatment as a multi-agent coordination problem offers a promising path toward safer and more coherent multidisease management.
Pick a starting point or write your own. Challenges run in the background, so you can keep reading while the AI investigates.
No challenges yet. Disagree with the review? Ask the AI to revisit a specific claim.